Literature DB >> 1348015

Biochemical characterization of resistance to mitoxantrone and adriamycin in Caco-2 human colon adenocarcinoma cells: a possible role for glutathione S-transferases.

W H Peters1, H M Roelofs.   

Abstract

Cytotoxicity of Adriamycin on human colon adenocarcinoma cell lines was investigated. Concentrations of Adriamycin producing 50% inhibition were very similar in HT29, Sw480, Sw620, and Sw1116 cells, whereas Caco-2 cells were relatively insensitive. As compared to the Sw1116 cell line, Caco-2 cells were also insensitive to mitoxantrone. Sensitivity to cisplatin, 5-fluorouracil, or ethacrynic acid was comparable in both cell lines. To find the mechanism for this mitoxantrone and Adriamycin resistance, several potential Adriamycin-detoxifying systems were characterized and quantified in both Sw1116 and Caco-2 cells. No dramatic differences in glutathione content and expression of both selenium dependent- and independent glutathione peroxidase, UDP-glucuronyltransferase, and cytochrome P-450 were found. However, highly significant differences in glutathione S-transferase activity were present, the expression of both class pi and class alpha glutathione S-transferases being much higher in the Caco-2 cell line. In addition, a slightly higher content of P-170 glycoprotein was present in the Caco-2 cells. These findings suggest that glutathione S-transferases, and to a lesser extent the P-170 glycoprotein, may be involved in mitoxantrone and Adriamycin resistance of Caco-2 colon carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348015

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers.

Authors:  H Saito; Y Fukasawa; Y Otsubo; K Yamada; H Sezaki; S Yamashita
Journal:  Pharm Res       Date:  2000-06       Impact factor: 4.200

2.  Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.

Authors:  S D Raeissi; Z Guo; G L Dobson; P Artursson; I J Hidalgo
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

3.  Transport of celiprolol across human intestinal epithelial (Caco-2) cells: mediation of secretion by multiple transporters including P-glycoprotein.

Authors:  J Karlsson; S M Kuo; J Ziemniak; P Artursson
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

Review 4.  Cellular models for multiple drug resistance in cancer.

Authors:  M Clynes
Journal:  In Vitro Cell Dev Biol       Date:  1993-03

5.  Influence of clinical factors, diet, and drugs on the human upper gastrointestinal glutathione system.

Authors:  H Hoensch; I Morgenstern; G Petereit; M Siepmann; W H M Peters; H M J Roelofs; W Kirch
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

6.  Drug absorption limited by P-glycoprotein-mediated secretory drug transport in human intestinal epithelial Caco-2 cell layers.

Authors:  J Hunter; B H Hirst; N L Simmons
Journal:  Pharm Res       Date:  1993-05       Impact factor: 4.200

7.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.

Authors:  Alex M Chen; Min Zhang; Dongguang Wei; Dirk Stueber; Oleh Taratula; Tamara Minko; Huixin He
Journal:  Small       Date:  2009-12       Impact factor: 13.281

8.  Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells.

Authors:  M E Cavet; M West; N L Simmons
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  Glutathione S-transferases and cytochrome P450 detoxifying enzyme distribution in human cerebral glioma.

Authors:  R Grant; J W Ironside
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 10.  Glutathione-related enzymes, glutathione and multidrug resistance.

Authors:  J A Moscow; K H Dixon
Journal:  Cytotechnology       Date:  1993       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.